RESULTS
One hundred and forty patients with pneumonia due to novel coronavirus
after renal transplantation were included in the analysis. Sixty-two
patients were classified into the azvudine group, 49 into the paxlovid
group, and 29 into the combined group of the two antivirals (Figure 1).
The mean age was 47.3 ± 11.3 years, and 90 cases (64.3%) were male
patients. Eight patients (5.7%) were vaccinated. Based on the
diagnostic criteria in the Chinese Novel Coronavirus Infection Treatment
Protocol (Trial Version 10), 1 (0.7%) of the included patients was
light, 112 (80.0%) were medium, 23 (16.4%) were heavy, and 4 (2.9%)
were critical.